Some AstraZeneca Investors Say Talk, Others Say Walk
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that only a small loophole is available to Pfizer to continue its pursuit of AstraZeneca, some shareholders in the U.K. company think it’s time for the board to talk; others are relieved a potential deal looks further from getting done.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.